Sumitomo Mitsui Trust Holdings Inc. raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 711,958 shares of the medical instruments supplier’s stock after buying an additional 50,455 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.33% of Becton, Dickinson and worth $138,910,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BDX. BlackRock Inc. increased its holdings in shares of Becton, Dickinson and by 2,427.8% during the first quarter. BlackRock Inc. now owns 16,542,028 shares of the medical instruments supplier’s stock valued at $3,034,470,000 after acquiring an additional 15,887,611 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and by 5.3% during the first quarter. Vanguard Group Inc. now owns 15,902,168 shares of the medical instruments supplier’s stock valued at $2,917,094,000 after acquiring an additional 796,034 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Becton, Dickinson and during the first quarter valued at $101,993,000. Waverton Investment Management Ltd bought a new position in shares of Becton, Dickinson and during the second quarter valued at $68,448,000. Finally, Montag & Caldwell LLC increased its holdings in shares of Becton, Dickinson and by 173.1% during the second quarter. Montag & Caldwell LLC now owns 516,821 shares of the medical instruments supplier’s stock valued at $100,837,000 after acquiring an additional 327,587 shares in the last quarter. 87.12% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/09/22/sumitomo-mitsui-trust-holdings-inc-purchases-50455-shares-of-becton-dickinson-and-company-bdx.html.

BDX has been the subject of several research analyst reports. BidaskClub downgraded Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies reiterated a “buy” rating and issued a $213.00 price objective on shares of Becton, Dickinson and in a report on Tuesday, September 12th. Bank of America Corporation reiterated a “buy” rating and issued a $225.00 price objective (up from $200.00) on shares of Becton, Dickinson and in a report on Friday, July 21st. Stifel Nicolaus reiterated a “buy” rating on shares of Becton, Dickinson and in a report on Wednesday, August 9th. Finally, Zacks Investment Research downgraded Becton, Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $196.93.

Becton, Dickinson and Company (BDX) opened at 191.56 on Friday. The stock has a market capitalization of $43.59 billion, a PE ratio of 55.48 and a beta of 1.06. The stock’s 50 day moving average price is $199.01 and its 200-day moving average price is $191.58. Becton, Dickinson and Company has a 52-week low of $161.29 and a 52-week high of $206.63.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the consensus estimate of $2.44 by $0.02. The firm had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. Becton, Dickinson and’s revenue for the quarter was down 5.1% compared to the same quarter last year. During the same period last year, the company earned $2.35 earnings per share. On average, equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.52%. The ex-dividend date of this dividend is Thursday, September 7th. Becton, Dickinson and’s dividend payout ratio (DPR) is 83.43%.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at $2,538,890.01. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the sale, the insider now directly owns 95,781 shares in the company, valued at $19,517,294.37. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 75,904 shares of company stock worth $15,242,688. 1.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.